Cellular Immunotherapy to Target HER-2 for Oncology is under clinical development by ImmunoRestoration and currently in Phase II for Ductal Carcinoma In Situ. According to GlobalData, Phase II drugs for Ductal Carcinoma In Situ have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cellular Immunotherapy to Target HER-2 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cellular Immunotherapy to Target HER-2 for Oncology overview
Cellular immunotherapy is under development for treatment of patients who are undergoing surgery for ductal carcinoma in situ of the breast and invasive breast cancer post neoadjuvant chemotherapy, triple negative breast cancer, HER2- breast cancer and HER2+ breast cancer. The drug candidate is administered as intranodal, intratumoral and intralesional injections. The drug candidate comprises of dendritic cells are pulsed with recombinant HER2/neu peptides.
ImmunoRestoration is a bio pharmaceutical company that develops and commercializes immunotherapeutic cancer vaccines. The company is investigating therapies to treat Ductal carcinoma in situ (DCIS), invasive breast cancer, glioblastoma, melanoma, pancreatic, prostate and gastric cancer. It utilizes ICAIT (Immune Conditioning via Activated Innate (autologous) Transfer), an integrated dendritic cell-based immunization system that helps patients in restoring their immune response. The company works in partnership with Moffitt Cancer Center, Pennies in Action, University of Pennsylvania and The Werner and Mary Henle Foundation. ImmunoRestoration is headquartered in Warminster, Pennsylvania, the US.
For a complete picture of Cellular Immunotherapy to Target HER-2 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.